CLIMB BIO, INC. Net Fee Amt
CLIMB BIO, INC. (CLYM) had Net Fee Amt of $17.15 thousand as of 2026-05-27, per its S-3 filed 2026-05-29.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-29
- 2026-05-27: Net Fee Amt $17.15K.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-27 | $17.15K S-3 · filed 2026-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |